<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268760</url>
  </required_header>
  <id_info>
    <org_study_id>605.1</org_study_id>
    <nct_id>NCT02268760</nct_id>
  </id_info>
  <brief_title>Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect</brief_title>
  <official_title>Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg, 1500 mg, 2000 mg and 2400 mg BILN 2061 ZW (PEG 400: Ethanol Solution) in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect of the Dose of 200 mg (Two-Stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Part and Subsequent Open Intraindividual Comparison Part)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the safety, tolerance and pharmacokinetics of 5 mg to 2400 mg BILN 2061 ZW

        1. In rising single doses

        2. With and without a 64 g fat breakfast at one selected dose
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in vital signs (systolic and diastolic blood pressure, pulse rate)</measure>
    <time_frame>Pre-dose, up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in laboratory tests</measure>
    <time_frame>Pre-dose and 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in 12-lead ECG</measure>
    <time_frame>Pre-dose, up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in physical examination</measure>
    <time_frame>Pre-dose and 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global assessment of tolerability by the investigator on a 4-point scale</measure>
    <time_frame>Up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of the analyte in plasma after a single dose administration (Cmax)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma from time 0 to infinity (AUC0-infinity)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax following a single dose administration (tmax)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total oral clearance of the analyte from plasma after oral administration, divided by F (bioavailability factor) (CL/F)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mean residence time of the analyte in plasma (MRT)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal elimination phase (Vz/F)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of intact drug excreted in urine (Au)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BILN 2061 ZW single rising doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BILN 2061 ZW fixed dose fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BILN 2061 ZW fixed dose fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILN 2061 ZW single rising doses</intervention_name>
    <arm_group_label>BILN 2061 ZW single rising doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILN 2061 ZW fixed dose</intervention_name>
    <arm_group_label>BILN 2061 ZW fixed dose fed</arm_group_label>
    <arm_group_label>BILN 2061 ZW fixed dose fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized breakfast</intervention_name>
    <arm_group_label>BILN 2061 ZW fixed dose fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects as determined by results of screening

          -  Signed written informed consent in accordance with good clinical practice (GCP) and
             local legislation

          -  Age ≥ 18 and ≤ 50 years

          -  Broca ≥ - 20 % and ≤ + 20 %

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders, including a history of viral hepatitis, or
             serological evidence of active Hepatitis B or Hepatitis C infection

          -  History of orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs which might influence the results of the trial within 10 days prior
             to administration or during the trial

          -  Participation in another trial with an investigational drug within 1 month prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on trial days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range and of clinical
             relevance

          -  History of any familial bleeding disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

